Accelerated Epigenetic Aging is Associated with Faster Glaucoma Progression: **A DNA Methylation Study**

Felipe A. Medeiros, MD, PhD^{1,2}, Achintya Varma, MS³, Alessandro A. Jammal, MD, PhD¹, Henry Tseng, MD, PhD², William K. Scott, PhD^{3,4}

- 1. Bascom Palmer Eye Institute, University of Miami, Miami, FL
- 2. Duke Eye Center and Department of Ophthalmology, Duke University, Durham, NC
- 3. John P. Hussman Institute for Human Genomics, University of Miami, FL
- 4. Dr. John T. MacDonald Foundation Department of Human Genetics, University of Miami, FL

Financial Support: Supported in part by National Institutes of Health/National Eye Institute grant EY029885 (F.A.M), Aging Team Science Grant from the University of Miami (F.A.M), Shaffer Grant from the Glaucoma Research Foundation (F.A.M). The funding organizations had no role in the design or conduct of this research.

Financial Disclosures: F.A.M.: AbbVie (C), Annexon (C); Carl Zeiss Meditec (C), Galimedix (C); Google Inc. (F); Heidelberg Engineering (F), nGoggle Inc. (P), Novartis (F); Stealth Biotherapeutics (C); Stuart Therapeutics (C), Thea Pharmaceuticals (C), Reichert (C, F). A.V.: None, A.A.J.: None, H.T.: Novartis (F). W.K.S.: None.

Abbreviations: Age acceleration (AgeAccel); central corneal thickness (CCT); cytosinephosphate-guanine (CpG); Duke Glaucoma Registry (DGR); Goldmann applanation tonometry (GAT); intraocular pressure (IOP); international classification of diseases (ICD); mean deviation (MD); primary open-angle glaucoma (POAG); retinal nerve fiber layer (RNFL)standard automated perimetry (SAP); Swedish Interactive Thresholding Algorithm (SITA).

Correspondence: Felipe A. Medeiros, MD, PhD, Bascom Palmer Eye Institute, 900 NW 17th St. Miami, FL. E-mail: fmedeiros@med.miami.edu

1 <u>ABSTRACT</u>

2

3 **Purpose:** To investigate the association between epigenetic age acceleration and glaucoma

- 4 progression.
- 5 **Design:** Retrospective cohort study.
- 6 Participants: 100 primary open-angle glaucoma (POAG) patients with fast progression and 100
- 7 POAG patients with slow progression.
- 8 Methods: Subjects were classified as fast or slow progressors based on rates of change in
- 9 standard automated perimetry (SAP) mean deviation (MD) and retinal nerve fiber layer (RNFL)
- 10 thickness. Epigenetic age was calculated using the Horvath, Hannum, PhenoAge, and GrimAge
- 11 clocks from DNA methylation profiles obtained from blood samples. Age acceleration
- 12 (AgeAccel) was defined as the residual from a linear regression of epigenetic age on chronologic
- 13 age, with positive values suggesting faster biological aging. Multivariable logistic regression
- 14 models estimated the association between AgeAccel and likelihood of fast progression, adjusting
- 15 for confounders.
- 16 Main Outcome Measures: Difference in epigenetic age acceleration between fast and slow
- 17 glaucoma progressors.
- 18 **Results:** The mean rate of SAP MD change in the fastest progressing eye was -1.06 dB/year
- 19 (95% CI: -1.28 to -0.85) for fast progressors compared to -0.10 dB/year (95% CI: -0.16 to -0.04)
- 20 for slow progressors (P<0.001). For RNFL thickness, corresponding values were -1.60 μ m/year
- 21 (95% CI: -1.97 to -1.23) and -0.76 μm/year (95% CI: -1.04 to -0.48), respectively (P<0.001).
- 22 Fast progressors demonstrated significantly greater age acceleration compared to slow
- progressors for the Horvath clock (mean difference = 2.93 years, 95% CI: 1.48 to 4.39, P<0.001)
- and Hannum clock (mean difference = 1.24 years, 95% CI: 0.03 to 2.46, P=0.045). In
- 25 multivariable models, each year of Horvath AgeAccel was associated with 15% higher odds of
- 26 fast progression (OR 1.15, 95% CI 1.07-1.23, P<0.001), after adjusting for sex, race, intraocular
- 27 pressure, central corneal thickness, baseline disease severity, smoking status and follow-up time.
- 28 Hannum and GrimAge clocks also showed significant associations with fast progression. The
- association between AgeAccel and fast progression was stronger in subjects with relatively low
- **30** IOP during follow-up.
- 31 Conclusion: Accelerated epigenetic aging was associated with faster glaucoma progression.
- 32 These findings suggest that faster biological age, as reflected in DNA methylation, may increase
- 33 optic nerve susceptibility to damage, highlighting epigenetic age as a potential prognostic
- 34 biomarker.
- 35

36 INTRODUCTION

37

38 Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons.¹ The disease affects over 100 million individuals worldwide and 39 40 is the leading cause of irreversible blindness. Although elevated intraocular pressure (IOP) is the 41 most widely accepted modifiable risk factor for glaucoma, a significant proportion of patients 42 continue to experience glaucomatous deterioration despite well-controlled IOP, suggesting that other factors contribute to the progression of glaucomatous damage.² Moreover, a subset of 30% 43 44 to 40% of patients exhibits normal-tension glaucoma, where damage occurs without concomitant 45 apparent IOP elevation. This indicates that factors other than IOP elevation may increase the optic nerve's susceptibility to damage.³ 46

47 Aging plays a pivotal role in glaucoma. The prevalence of glaucoma increases markedly with age.^{4, 5} However, the pathophysiology underlying increasing age as a risk factor for 48 49 glaucoma is not well understood. The increased prevalence of glaucoma in older individuals does 50 not seem to be explained solely by an increased prevalence of high IOP with aging.⁶⁻⁸ This 51 suggests that aging may increase the vulnerability of the optic nerve to IOP-related damage, 52 ultimately resulting in loss of retinal ganglion cells. This age-related increased vulnerability to 53 neural injury has also been observed in other neurodegenerative disorders, such as Alzheimer's 54 and Parkinson's disease, and may be related to mitochondrial dysfunction and impaired capacity to handle oxidative stress, among other factors.⁹⁻¹⁵ Epigenetics, the study of alterations in gene 55 56 expression without changes in the DNA sequence, has shown promise in understanding aging 57 and age-related diseases. The biological age encapsulated in our epigenome, as reflected by DNA 58 methylation patterns, often diverges from our chronological age. The "epigenetic clock" theory,

59	conceptualized by Horvath, ¹⁶ leverages these methylation changes at specific cytosine-
60	phosphate-guanine (CpG) sites as a timekeeper of biological aging. The disparities between
61	biological (epigenetic) and chronological age have been associated with several age-related
62	diseases, such as cardiovascular disease, neurodegeneration, and cancer. An advanced epigenetic
63	age relative to chronological age may signify accelerated biological aging and increased disease
64	risk. ¹⁷ Despite these observations, no study has yet been conducted on epigenetic age and
65	glaucoma.

66 In the present study, we hypothesized that disparities between epigenetic and 67 chronological age may be a significant risk factor in explaining glaucoma progression. 68 Specifically, we hypothesized that individuals with faster disease progression would demonstrate 69 an accelerated biological age, as indicated by a greater divergence between epigenetic and 70 chronological age, compared to those with slower progression. Uncovering the relationship 71 between epigenetic age and glaucoma progression could provide novel insights into the 72 pathophysiology of the disease and offer a more accurate prognostic tool than chronological age 73 alone.

74

75 METHODS

This study involved a cohort of subjects that were part of the Duke Glaucoma Registry
(DGR), a large database of electronic medical records developed at Duke University, Durham,
North Carolina. The database consisted of adults 18 years or older with glaucoma or glaucoma
suspect diagnoses who were evaluated at the Duke Eye Center or its satellite clinics between
January 2009 and June 2023. The database has been described in detail elsewhere and has been

used for several studies investigating risk factors for glaucoma.^{3, 18-21} A subset of participants, 81 82 described below, was recruited for blood sample collection. Blood sample analyses were 83 performed at the John P. Hussman Institute for Human Genomics (HIHG) at the University of 84 Miami, Florida. The Duke University and the University of Miami Institutional Review Boards 85 approved this study. Informed consent was obtained from all participants. All methods adhered to 86 the tenets of the Declaration of Helsinki for research involving human subjects and were 87 conducted in accordance with regulations of the Health Insurance Portability and Accountability 88 Act.

89 The database used for this study contained clinical information from baseline and follow-90 up visits, including patient diagnostic and procedure codes, medical history, smoking history, 91 best-corrected visual acuity, slit-lamp biomicroscopy, IOP measurement using the Goldmann 92 applanation tonometry (GAT; Haag-Streit, Konig, Switzerland), central corneal thickness (CCT), 93 gonioscopy, ophthalmoscopy examination, optic disc photographs, and the results of all standard 94 automated perimetry (SAP) and optical coherence tomography (OCT) exams. SAP testing was 95 performed with the Humphrey Field Analyzer (Carl Zeiss Meditec, Dublin, CA) using the 96 Swedish Interactive Thresholding Algorithm (SITA) 24-2 fast strategy. OCT was performed with 97 the Spectralis SDOCT (Heidelberg Engineering, Dossenheim, Germany). A reliable SAP was 98 defined as having fixation loss rate less than 25% and false-positive rate less than 15%. Visual 99 fields were manually reviewed for artifacts such as lid and rim artifacts, fatigue effects, 100 inappropriate fixation, and evidence that the visual field results were due to a disease other than 101 glaucoma. Retinal nerve fiber layer (RNFL) thickness measurements were obtained from a 12-102 degree (for single circle scans) or a 3.45mm-diameter peripapillary circle scan (for scans from 103 the Glaucoma Mode Premium Edition) acquired using the Spectralis SD OCT, as described in

detail previously.²² Tests were acquired using the latest available software version at the time of
the scan and exported using the latest available version at the time of the analysis (Software
version 6.8). Scans were manually reviewed for the presence or artifacts, decentration, or
segmentation errors. Tests with quality score below 15, or with segmentation errors, evidence of
decentration or artifacts were also excluded. For each scan, the global average RNFL thickness
was calculated as the average of thicknesses of all points from the 360 degrees around the optic
nerve head.

111 Participant selection

112 This study included a subset of participants from the DGR who were recruited for 113 prospective blood sample collection. Subjects were contacted during their regular clinic visits 114 and invited to provide blood samples for genetic analysis. Selection criteria included a diagnosis 115 of primary open-angle glaucoma (POAG) in both eyes, confirmed by international classification 116 of diseases (ICD) codes at the baseline visit, as well as the availability of longitudinal data in the 117 DGR. 1,251 POAG patients provided blood samples. A total of 10 ml of blood was collected 118 from each participant, processed, and stored for future analysis. Blood collections took place 119 between June 2021 and June 2023.

120 Fast versus slow progression classification

Subjects were classified as either fast or slow progressors based on available SAP and SD OCT tests. Ordinary least squares linear regression was used to estimate the slopes of change in SAP mean deviation (MD) and RNFL thickness over time. Subjects who did not clearly fit into either group were excluded from further analyses to maximize the distinction between fast and slow progressors and avoid including ambiguous cases. Fast progressors were defined as having

at least one eye with either a statistically significant SAP MD slope faster than -0.5 dB/year or a
statistically significant global RNFL thickness slope faster than -1.0 µm/year. In contrast, slow
progressors were required to meet all of the following criteria in both eyes: non-significant SAP
MD slope, non-significant global RNFL thickness slope, a minimum follow-up time of 5 years,
and no history of trabeculectomy or tube shunt surgery.

131 These criteria were designed to create a clearly divergent sample, thereby enhancing the 132 ability to test the primary hypothesis of the study. No minimum follow-up time was required for 133 fast progressors, allowing the inclusion of patients with rapid progression over shorter periods. 134 While a history of glaucoma surgery was not an exclusion criterion for fast progressors, SAP and 135 OCT tests were censored post-surgery and excluded from the calculation of progression rates. 136 Importantly, we use the term 'slow progressor' rather than 'non-progressor' because it is not 137 possible to guarantee that these subjects would not have progressed by other measures. The 138 primary objective was to ensure that any changes in the slow progressor group would likely be 139 minimal, resulting in a significant difference in disease trajectory between the two groups.

140 Sample Size Calculation

141 The primary hypothesis of this study was that individuals with faster glaucoma 142 progression would demonstrate an accelerated biological age, indicated by a greater discrepancy 143 between epigenetic age and chronological age, compared to those with slower progression. 144 Given the high costs associated with DNA methylation analysis, only a subset of subjects with 145 available blood samples underwent epigenetic age calculation. A power analysis determined that 146 a sample size of 100 subjects per group would provide 80% power to detect a minimum 147 difference of 2.0 years between the two groups in the difference between epigenetic and 148 chronological age, assuming a standard deviation of 5.0 and an alpha level of 0.05.

Consequently, from the 1,251 subjects with available blood samples, 100 individuals with slow
progression and 100 with fast progression were selected. These 200 samples were then subjected
to DNA extraction, methylation profiling and epigenetic age calculation.

152 DNA Extraction, Methylation Processing, and Quality Control

153 Immediately after collection, whole blood samples were centrifuged to separate the 154 different components. The separated components, including plasma, buffy coat, and red blood 155 cells, were then frozen at -80° C for preservation. At a later stage, the buffy coat was thawed and 156 processed for DNA extraction. Upon thawing, the buffy coat was centrifuged at 1,500 x g for 10 157 minutes to concentrate the cells. Genomic DNA was subsequently extracted from the buffy coat 158 using the QIA amp DNA Blood Mini Kit (Qiagen, Hilden, Germany), following the 159 manufacturer's protocol. The quality of the extracted DNA was assessed using a NanoDrop 160 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). The absorbance ratios at 260/280 161 nm and 260/230 nm were measured, with DNA samples considered high quality if the A260/280 162 ratio fell between 1.8 and 2.0, and the A260/230 ratio was \geq 2.0. The quantity and concentration 163 of DNA were evaluated using a Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA). 164 Additionally, DNA integrity was qualitatively evaluated using agarose gel electrophoresis to 165 identify samples with high molecular weight bands suitable for analysis. Sample concentration 166 was normalized to 50 ng/µL and arrayed in Azenta 0.5 ml barcoded tubes in racks of 96. 167 Genome-wide DNA methylation was assessed using the Illumina Infinium 168 MethylationEPIC v2 BeadChip (Illumina, San Diego, CA), which interrogates approximately 169 930,000 cytosine-phosphate-guanine (CpG) sites across the human genome. DNA samples (500 170 ng each) were bisulfite-converted using the EZ DNA Methylation Kit (Zymo Research, Irvine, 171 CA) according to the manufacturer's instructions, which converts unmethylated cytosines to

172 uracil while leaving methylated cytosines unchanged. The bisulfite-converted DNA was then 173 hybridized to the MethylationEPIC v2 BeadChip, and the arrays were scanned using the Illumina 174 iScan system. Data files created by the Illumina iScan were analyzed using the Illumina 175 GenomeStudio Methylation module software program. To ensure the reliability of the 176 methylation data, several quality control measures were implemented following established 177 protocols in the literature. Raw methylation intensity data were first preprocessed using the R 178 package minfi, which includes background correction, normalization, and calculation of detection p-values to assess the quality of individual probes.²³ Probes with detection p-values 179 above a threshold of 0.01 in more than 5% of samples were excluded from further analysis.²⁴ 180 181 Methylation data were then mapped to the genome, and only those probes that passed stringent 182 quality control criteria were retained for epigenetic age calculation.

183 Epigenetic Age Calculation

184 Epigenetic age was calculated using several established algorithms, each of which applies
185 specific sets of CpG sites to estimate biological age:

Horvath Clock: The Horvath clock is an epigenetic age estimator that utilizes a linear combination of methylation levels at 353 specific CpG sites to calculate an individual's biological age; these sites were selected from data generated from multiple tissue types, including blood, skin, brain and other internal organs.²⁵ This "universal" epigenetic clock is designed to provide a robust estimate of biological age, regardless of tissue source, and has been widely validated for its accuracy in correlating with chronological age across a diverse range of tissues.

Hannum Clock: The Hannum clock is an epigenetic age predictor specifically tailored
 for use in whole blood samples.²⁶ It is based on methylation data from 71 CpG sites that

195		are strongly associated with age-related changes in blood. The model calculates
196		biological age by assessing methylation patterns at these sites, which reflect the
197		physiological aging process in hematopoietic cells, making it potentially useful for
198		studies focusing on blood-based biomarkers of aging.
199	٠	PhenoAge : The PhenoAge clock, developed by Levine et al., ²⁷ integrates DNA
200		methylation data from 513 CpG sites with clinical phenotypes and mortality risk
201		indicators to provide a comprehensive measure of biological aging. Unlike traditional
202		epigenetic clocks that primarily estimate chronological age, PhenoAge is designed to
203		capture the physiological decline associated with morbidity and mortality risk.
204	•	GrimAge: GrimAge is an epigenetic clock that combines methylation data from specific
205		CpG sites with inferred plasma protein levels and cumulative smoking exposure to
206		predict time to death and other aging-related outcomes. ²⁸
207		Methylation data for the probes was submitted to the DNA Methylation Age Calculator
208	website	e (dnamage.clockfoundation.org). ²⁵ For each one of these clocks, age acceleration
209	(AgeA	ccel) was calculated as the residual from a linear regression model of the corresponding
210	epigen	etic clock and chronological age. Residual variables were then named AgeAccelHorvath,
211	AgeAc	celHannum, AgeAccelPheno and AgeAccelGrim, corresponding to the clocks listed
212	above.	Positive values in these variables suggest a higher epigenetic age relative to chronological
213	age and	d thus faster biological aging, while negative values suggest slower biological aging.
214	Statisti	ical Analysis
215		Correlations between chronological age and each epigenetic age measure were assessed
216	using F	Pearson's correlation coefficients. Differences in AgeAccel (epigenetic age acceleration)

between fast and slow glaucoma progressors were evaluated using Student's t-tests. Additionally,

217

218	multivariable logistic regression models were employed to estimate adjusted odds ratios (ORs)
219	and 95% confidence intervals (CIs) for the association between AgeAccel variables and the
220	likelihood of fast progression. These models were adjusted for key potential confounders,
221	including gender, race, smoking status, IOP, CCT, and baseline disease severity, as measured by
222	baseline MD. For IOP, both the mean and peak values recorded during follow-up were analyzed.
223	Since IOP, CCT, and baseline MD are eye-specific variables, the mean values of both eyes were
224	utilized in the logistic regression models. Furthermore, considering that blood samples were
225	collected during follow-up rather than at baseline, the time from baseline to the date of blood
226	collection was calculated and included as a potential confounder in the multivariable models.
227	Statistical analyses were completed in R (version 4.4.1, R Foundation for Statistical
228	Computing, Vienna, Austria).
229	

230 RESULTS

231 The study included 100 POAG patients diagnosed with fast glaucoma progression and 232 100 POAG patients with slow progression. Table 1 shows demographic and clinical 233 characteristics of the 2 groups. Mean follow-up time was 10.3 years (95% CI: 9.0 - 11.5) for fast 234 progressors and 11.0 years (95% CI: 9.6 - 12.3) for slow progressors, with no statistically 235 significant difference between the groups (P = 0.45). The mean rate of change in SAP MD, 236 averaged across both eyes, was significantly different between the groups: -0.63 dB/year (95% 237 CI: -0.77 - -0.48) in fast progressors compared to 0.01 dB/year (95% CI: -0.06 - 0.07) in slow 238 progressors (P < 0.001). When considering the eye with the faster rate of SAP MD decline, the 239 mean rates were -1.06 dB/year (95% CI: -1.28 – -0.85) for fast progressors and -0.10 dB/year

240	(95% CI: $-0.160.04$) for slow progressors (P < 0.001). Over the follow-up period, fast
241	progressors lost an average of 8.2 dB (95% CI: 6.9 – 9.5) of MD in the fastest progressing eye,
242	compared to a loss of only 1.4 dB (95% CI: $0.8 - 1.9$) in the slow progressor group. For OCT
243	RNFL thickness, the mean rate of change in the fastest progressing eye was -1.60 $\mu m/year$ (95%
244	CI: -1.97 – -1.23) for fast progressors, compared to -0.76 (95% CI: -1.04 – -0.48) $\mu m/year$ for
245	slow progressors ($P < 0.001$). Mean IOP during follow-up was similar between the groups, at
246	15.0 mmHg (95% CI: 14.4 – 15.6) for fast progressors and 15.3 mmHg (95% CI: 14.7 – 16.0) for
247	slow progressors ($P = 0.39$). However, peak IOP during follow-up, averaged across both eyes,
248	was higher in fast progressors compared to slow progressors (23.8 mmHg [95% CI: $22.0 - 25.5$)
249	vs. 20.5 mmHg [95% CI: 19.5 – 21.6], respectively; P = 0.002).
250	Epigenetic age was strongly correlated with chronological age across all epigenetic clock
251	methods (Figure 1). The Horvath clock showed a Pearson correlation coefficient of $r = 0.83$
252	(95% CI: $0.78 - 0.87$) with chronological age (P<0.001). Similarly, the Hannum clock
253	demonstrated a correlation of $r = 0.85$ (95% CI: 0.80 – 0.90; P<0.001), while the PhenoAge
254	clock showed a correlation of $r = 0.81$ (95% CI: 0.76 – 0.87; P<0.001). The GrimAge clock had
255	a slightly lower but still substantial correlation with chronological age (r = 0.70 ; 95% CI: $0.62 - 0.00$
256	0.78; P<0.001).

Table 2 shows the mean age acceleration values for fast and slow progressors according to the different epigenetic clocks, while **Figure 2** shows the distribution of these values across the two groups. For AgeAccelHorvath, fast progressors had significantly greater age acceleration compared to those with slow progression, with a mean difference of 2.93 years (95% CI: 1.48 to 4.39; P < 0.001). Similarly, faster acceleration was observed with AgeAccelHannum, with a mean difference of 1.24 years (95% CI: 0.03 to 2.46; P = 0.045). No statistically significant

263	differences were found for AgeAccelPheno or AgeAccelGrim. For AgeAccelPheno, the mean
264	difference between fast and slow progressors was 1.06 years (95% CI: -0.51 to 2.64; $P = 0.185$).
265	Likewise, AgeAccelGrim showed a mean difference of 1.49 years (95% CI: -0.17 to 3.14; P =
266	0.079), which also did not reach statistical significance.
267	Table 3 shows the results of multivariable logistic regression models for the association
268	between different age acceleration variables and the likelihood of fast progression, adjusted for
269	relevant covariates. AgeAccelHorvath demonstrated the strongest association with fast
270	progression (OR: 1.15 per year of acceleration, 95% CI: 1.07-1.23, P<0.001). AgeAccelHanum
271	and AgeAccelGrim also showed significant associations (OR: 1.07, 95% CI: 1.00-1.15, P=0.049
272	and OR: 1.07, 95% CI: 1.01-1.14, P=0.034, respectively). AgeAccelPheno did not reach
273	statistical significance (OR: 1.04, 95% CI: 0.99-1.10, P=0.141). Lower baseline MD, indicating
274	worse severity at baseline, was significantly associated with fast progression across all models
275	(OR ranging from 1.12 to 1.13 per dB lower, P=0.001 for all models). Peak IOP was also a
276	significant predictor in all models, with the OR consistently at 1.09 or 1.10 per mmHg increase
277	(P≤0.001 for all models). Male sex showed a trend towards higher odds of fast progression,
278	although this did not reach statistical significance. CCT, race, follow-up time, and smoking status
279	were not significantly associated with fast progression in any of the models.
280	We further examined the effect of age acceleration on the likelihood of fast progression in

POAG subjects who had no history of elevated IOP, defined as those with both eyes never
exceeding an IOP of 21 mmHg (Table 4, supplemental). Statistically significant differences
were observed across all age acceleration metrics, except for AgeAccelPheno. Specifically, for

AgeAccelHorvath, the mean difference between fast and slow progressors was 4.69 years (95%

285 CI: 2.46 to 6.93), indicating acceleration in epigenetic aging among fast progressors.

286

287 DISCUSSION

288	To our knowledge, this study is the first to explore the link between epigenetic age and
289	glaucoma progression, offering new insights into the role of biological aging in this
290	neurodegenerative disease. Our findings revealed a significant association between accelerated
291	epigenetic age and faster glaucoma progression, suggesting that biological aging processes may
292	increase optic nerve susceptibility to glaucomatous damage.

293 The characterization of fast and slow progressors in our study was rigorous and designed 294 to create a clearly divergent sample, enhancing the ability to test our primary hypothesis. The 295 marked contrast in rates of change between fast and slow progressors (-1.06 \pm 1.08 dB/year vs -296 0.10 ± 0.33 dB/year in the fastest progressing eye, respectively) highlights the clinical 297 significance of our findings and validates our sample construction strategy. Over the follow-up period, fast progressors lost an average of 8.2 dB in MD in their fastest progressing eye, 298 299 compared to only 1.4 dB in the slow progressor group, highlighting the substantial difference in 300 disease trajectory between these groups.

As expected, all epigenetic clocks demonstrated strong correlations with chronological age in our study population, with Pearson correlation coefficients ranging from 0.70 to 0.85. Following previously established methods, we calculated age acceleration as the residual from a linear regression model of each epigenetic clock and chronological age.²⁵ This allowed us to quantify the degree to which an individual's biological age, as measured by DNA methylation patterns, deviates from their chronological age. Using these age acceleration measures, our results demonstrated that individuals with faster glaucoma progression exhibited accelerated

biological aging, as indicated by the various epigenetic clocks. The Horvath clock showed the
strongest association, with fast progressors demonstrating a mean age acceleration of almost 3
years compared to slow progressors. This finding was further supported by the multivariable
logistic regression model, which showed that for each year of age acceleration according to the
Horvath clock, the odds of fast progression increased by 15% (OR: 1.15, 95% CI: 1.07-1.23,
P<0.001), after controlling for other clinical and demographic variables that potentially affect
progression speed.

315 The stronger association observed with the Horvath clock may be attributed to its 316 "universal" nature. Horvath developed this epigenetic clock using samples from 51 different 317 tissues and cell types, including brain, whole blood, heart, kidney, liver, lung, among others.²⁵ 318 While it did not specifically include eye tissue, it did incorporate brain tissue samples, which 319 may be particularly relevant given the neurodegenerative nature of glaucoma. The Horvath 320 clock's ability to predict age across diverse tissues suggests it captures fundamental aging 321 processes that may be applicable to the eye and optic nerve. This universality might explain its 322 stronger association with glaucoma progression in our study, as it likely reflects systemic aging 323 processes that could affect the vulnerability of retinal ganglion cells and their axons. The 324 Hannum clock, specifically designed for blood samples, also showed a significant association, 325 albeit weaker than the Horvath clock. Interestingly, the PhenoAge clock showed the weakest 326 association, likely due to its construction. PhenoAge incorporates clinical phenotypes and 327 mortality risk indicators, such as albumin, creatinine, glucose, and inflammatory markers, which may not be directly linked to glaucomatous damage.²⁷ While these markers are relevant to 328 329 overall health and aging, their connection to the specific mechanisms of glaucoma may be 330 limited. The GrimAge clock, which showed an intermediate association, was developed to

predict mortality and health span using DNA methylation-based biomarkers for plasma proteins
and smoking history.²⁸ Some of these factors, like smoking, may be relevant to glaucoma
progression, while others may not directly influence optic nerve vulnerability, potentially
explaining its intermediate performance.

335 The association between accelerated biological age and faster glaucoma progression may 336 be explained by several mechanisms. Advanced biological age could increase the susceptibility 337 of the optic nerve to damage due to a reduced ability to handle oxidative stress, which is 338 recognized as a contributing factor to glaucomatous neurodegeneration.¹ Aging is associated with 339 mitochondrial dysfunction and decreased antioxidant defenses, potentially making retinal ganglion cells more vulnerable to IOP-related stress.²⁹⁻³³ Additionally, age-related biomechanical 340 341 changes in the lamina cribrosa and peripapillary sclera could alter the optic nerve head response to IOP, potentially increasing susceptibility to axonal damage.^{14, 34} 342

343 Our study found that age acceleration remained a significant predictor of fast glaucoma 344 progression, even after adjusting for known risk factors such as IOP and baseline disease 345 severity. The association of IOP and baseline MD with fast progression found in our models is 346 similar to previous studies, supporting our approach. However, the independent association of 347 epigenetic age acceleration suggests that biological aging contributes additional risk beyond 348 these established factors. The observed differences in epigenetic age acceleration between fast 349 and slow progressors were clinically significant, as depicted in the probability plot (Figure 3). 350 This plot, based on the Horvath clock and adjusted for key confounders such as sex, race, peak 351 IOP, baseline disease severity, CCT, and follow-up time, demonstrated a strong association 352 between age acceleration and the likelihood of fast glaucoma progression. A 10-year increase in 353 age acceleration was associated with a substantial increase in the probability of fast progression,

nearly doubling it. For example, at an age acceleration of approximately +10 years, the
probability of fast progression approached 70%. These findings highlight the potential clinical
importance of epigenetic age acceleration as a predictor of glaucoma progression, beyond the
influence of established risk factors.

A particularly interesting finding was the stronger association between age acceleration and fast progression in subjects with low IOP, i.e., those who never had IOP greater than 21mmHg. This aligns with clinical observations that low-pressure glaucoma is rarely seen in young individuals and supports the notion that biological aging may increase the optic nerve susceptibility to damage even at normal IOP levels. The mean difference in AgeAccelHorvath between fast and slow progressors in this subgroup was almost 5 years, substantially larger than in the overall cohort, emphasizing the potential importance of biological aging in these cases.

365 The association between accelerated biological aging and increased susceptibility to 366 damage is not unique to glaucoma and has been observed in other neurodegenerative diseases. 367 For instance, in Alzheimer's disease (AD), previous studies have found associations between epigenetic age acceleration and disease risk or progression.^{35, 36} Levine et al. reported that 368 369 individuals with greater epigenetic age acceleration in brain tissue showed more rapid progression of AD neuropathology.³⁵ Similarly, McCartney et al. found that DNA methylation 370 371 age acceleration in blood was associated with cognitive decline and dementia risk.³⁶ In 372 Parkinson's disease, another neurodegenerative condition, Horvath and Ritz reported that patients exhibited accelerated epigenetic aging in brain tissues compared to controls.³⁷ These parallels 373 374 with other neurodegenerative diseases support the notion that accelerated biological aging may 375 increase susceptibility to neuronal damage across various conditions, including glaucoma.

376 The association between accelerated biological aging and glaucoma progression suggests 377 potential for neuroprotective strategies targeting aging processes. Compounds like nicotinamide 378 mononucleotide (NMN) and nicotinamide, precursors to NAD+, have shown promise in animal studies. Williams et al.³⁸ demonstrated that nicotinamide administration prevented glaucoma in 379 380 aged mice and those with ocular hypertension. Recent pilot human studies have also shown potential benefits. Hui et al.³⁹ conducted a phase 2 clinical trial demonstrating that high-dose oral 381 382 nicotinamide improved inner retinal function in glaucoma patients. Additionally, De Moraes et 383 al.⁴⁰ reported that oral nicotinamide supplementation enhanced retinal ganglion cell function in 384 patients with early-stage glaucoma. While these results are promising, larger and longer-term 385 studies are needed to fully establish the efficacy and safety of these compounds in human 386 glaucoma patients. Nonetheless, these findings, coupled with our observations on epigenetic age 387 acceleration, highlight the potential of targeting aging processes as a novel therapeutic approach 388 in glaucoma management.

389 While our study provides compelling evidence for the role of biological aging in 390 glaucoma progression, several limitations must be acknowledged. Primarily, blood samples for 391 epigenetic analysis were collected after progression had occurred, precluding the establishment 392 of a causal relationship. Although we attempted to control for this by including follow-up time to 393 blood collection in our multivariable models, prospective studies are needed to confirm the 394 predictive value of epigenetic age acceleration in glaucoma progression. Another limitation is the 395 potential impact of glaucoma treatment on our results. While we controlled for IOP in our 396 models, the effects of various treatments on epigenetic age acceleration are unknown and could 397 potentially confound our findings. Additionally, our study was conducted in a single center, 398 which may limit the generalizability of our results to other populations.

- 399 In conclusion, this study provides the first evidence of an association between accelerated
- 400 epigenetic aging and faster glaucoma progression. Our findings suggest that biological age, as
- 401 measured by DNA methylation patterns, may be an important factor in determining an increased
- 402 susceptibility to glaucomatous damage. Future prospective studies are needed to validate these
- 403 findings and explore the potential of epigenetic age as a biomarker for glaucoma progression.

405 **REFERENCES**

406 Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a 1. 407 review. JAMA 2014;311(18):1901-11. 408 2. Susanna BN, Ogata NG, Jammal AA, et al. Corneal Biomechanics and Visual Field 409 Progression in Eyes with Seemingly Well-Controlled Intraocular Pressure. Ophthalmology 410 2019;126(12):1640-6. 411 3. Jammal AA, Berchuck SI, Thompson AC, et al. The Effect of Age on Increasing 412 Susceptibility to Retinal Nerve Fiber Layer Loss in Glaucoma. Invest Ophthalmol Vis Sci 413 2020;61(13):8. 414 4. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in 415 Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103(10):1661-9. 416 Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular 5. 417 hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111(8):1439-418 48. 419 Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous 6. 420 progression between untreated patients with normal-tension glaucoma and patients with 421 therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126(4):487-97. 422 Leske MC, Connell AM, Wu SY, et al. Distribution of intraocular pressure. The Barbados 7. 423 Eye Study. Arch Ophthalmol 1997;115(8):1051-7. 424 Rochtchina E, Mitchell P, Wang JJ. Relationship between age and intraocular pressure: 8. 425 the Blue Mountains Eve Study. Clin Exp Ophthalmol 2002;30(3):173-5. 426 9. Friberg TR, Lace JW. A comparison of the elastic properties of human choroid and sclera. 427 Exp Eye Res 1988;47(3):429-36. 428 Quigley HA, Addicks EM. Regional differences in the structure of the lamina cribrosa 10. 429 and their relation to glaucomatous optic nerve damage. Arch Ophthalmol 1981;99(1):137-43. 430 Grossniklaus HE, Nickerson JM, Edelhauser HF, et al. Anatomic alterations in aging and 11. 431 age-related diseases of the eye. Invest Ophthalmol Vis Sci 2013;54(14):ORSF23-7. 432 12. Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch's 433 membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 434 1994;35(6):2857-64. 435 13. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog 436 Retin Eye Res 2002;21(4):359-93. 437 Burgoyne CF, Downs JC, Bellezza AJ, et al. The optic nerve head as a biomechanical 14. 438 structure: a new paradigm for understanding the role of IOP-related stress and strain in the 439 pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res 2005;24(1):39-440 73. 441 15. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. 442 Prog Retin Eye Res 2005;24(5):612-37. 443 16. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of 444 ageing. Nat Rev Genet 2018;19(6):371-84. 445 17. Marioni RE, Shah S, McRae AF, et al. DNA methylation age of blood predicts all-cause 446 mortality in later life. Genome Biol 2015;16(1):25. 447 18. Jammal AA, Berchuck SI, Mariottoni EB, et al. Blood Pressure and Glaucomatous 448 Progression in a Large Clinical Population. Ophthalmology 2022;129(2):161-70.

449 19. Jammal AA, Thompson AC, Mariottoni EB, et al. Impact of Intraocular Pressure Control

- 450 on Rates of Retinal Nerve Fiber Layer Loss in a Large Clinical Population. Ophthalmology451 2021;128(1):48-57.
- 452 20. Jammal AA, Thompson AC, Mariottoni EB, et al. Rates of Glaucomatous Structural and
- 453 Functional Change From a Large Clinical Population: The Duke Glaucoma Registry Study. Am J454 Ophthalmol 2021;222:238-47.
- 455 21. Youssif AA, Onyekaba NA, Naithani R, et al. Social history and glaucoma progression:
- the effect of body mass index, tobacco and alcohol consumption on the rates of structural changein patients with glaucoma. Br J Ophthalmol 2024.
- 458 22. Leite MT, Rao HL, Zangwill LM, et al. Comparison of the diagnostic accuracies of the
 459 Spectralis, Cirrus, and RTVue optical coherence tomography devices in glaucoma.
- 460 Ophthalmology 2011;118(7):1334-9.
- 461 23. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive
- 462 Bioconductor package for the analysis of Infinium DNA methylation microarrays.
- **463** Bioinformatics 2014;30(10):1363-9.
- 464 24. Pidsley R, CC YW, Volta M, et al. A data-driven approach to preprocessing Illumina
 465 450K methylation array data. BMC Genomics 2013;14:293.
- 466 25. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol467 2013;14(10):R115.
- 468 26. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal
 469 quantitative views of human aging rates. Mol Cell 2013;49(2):359-67.
- 470 27. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and
 471 healthspan. Aging (Albany NY) 2018;10(4):573-91.
- 472 28. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan
 473 and healthspan. Aging (Albany NY) 2019;11(2):303-27.
- 474 29. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative
 475 diseases. Nature 2006;443(7113):787-95.
- 476 30. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and
 477 consequences. Prog Retin Eye Res 2006;25(5):490-513.
- 478 31. Crowston JG, Kong YX, Trounce IA, et al. An acute intraocular pressure challenge to
 479 assess retinal ganglion cell injury and recovery in the mouse. Exp Eye Res 2015;141:3-8.
- 480 32. Kong YX, van Bergen N, Bui BV, et al. Impact of aging and diet restriction on retinal
 481 function during and after acute intraocular pressure injury. Neurobiol Aging 2012;33(6):1126
 482 e15-25.
- 483 33. Levkovitch-Verbin H, Vander S, Makarovsky D, Lavinsky F. Increase in retinal ganglion
 484 cells' susceptibility to elevated intraocular pressure and impairment of their endogenous
 485 neuroprotective mechanism by age. Mol Vis 2013;19:2011-22.
- 486 34. Liu B, McNally S, Kilpatrick JI, et al. Aging and ocular tissue stiffness in glaucoma. Surv
 487 Ophthalmol 2018;63(1):56-74.
- 488 35. Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is
 489 associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive
 490 functioning. Aging (Albany NY) 2015;7(12):1198-211.
- 491 36. McCartney DL, Stevenson AJ, Walker RM, et al. Investigating the relationship between
- 492 DNA methylation age acceleration and risk factors for Alzheimer's disease. Alzheimers Dement
 493 (Amst) 2018;10:429-37.

- 494 37. Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of
- 495 Parkinson's disease patients. Aging (Albany NY) 2015;7(12):1130-42.
- 496 38. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B(3) modulates mitochondrial
 497 vulnerability and prevents glaucoma in aged mice. Science 2017;355(6326):756-60.
- 498 39. Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with
- 499 nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clin Exp
- 500 Ophthalmol 2020;48(7):903-14.
- 501 40. De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and Pyruvate for
- 502 Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA
- **503** Ophthalmol 2022;140(1):11-8.

505 FIGURE LEGENDS

506

523

507	Figure 1. Scatter plots illustrating the relationship between epigenetic age (y-axis) and
508	chronological age (x-axis) for four epigenetic clocks: (A) Horvath, (B) Hannum, (C) PhenoAge,
509	and (D) GrimAge. Each point represents an individual patient. Pearson correlation coefficients
510	(r) are shown for each clock. Epigenetic age was calculated using DNA methylation data from
511	blood samples collected during the follow-up period. Chronological age is the age at blood
512	collection.
513	Figure 2. Histograms depicting the distribution of epigenetic age acceleration values for (A)
514	Horvath, (B) Hannum, (C) PhenoAge, and (D) GrimAge clocks in fast (black) and slow (grey)
515	glaucoma progressors. Age acceleration was calculated as the residual from a linear regression of
516	epigenetic age on chronological age. Positive values indicate an epigenetic age greater than
517	chronological age.
518	Figure 3. Predicted probability of fast glaucoma progression based on Horvath age acceleration
519	The curve shows the predicted probability of fast glaucoma progression (y-axis) as a function of
520	Horvath age acceleration (x-axis), derived from the multivariable logistic regression model. Age
521	acceleration was calculated as the residual from a linear regression of Horvath epigenetic age on
522	chronological age. The shaded area represents the 95% confidence interval. The model is

adjusted for sex, race, peak intraocular pressure, baseline mean deviation, central corneal

524 thickness and follow-up time until blood collection.

Characteristic	Slow Progressors (n=100)	Fast Progressors (n=100)	Р
Age at baseline (years)	61.8 ± 9.0	60.6 ± 11.8	0.43
Age at blood collection (years)	73.4 ± 8.3	71.7 ± 10.2	0.20
Sex (female), n (%)	59 (59%)	58 (58%)	0.89
Race (Black or African American), n (%)	21 (21%)	22 (22%)	0.86
Smoking status, yes, n (%)	5 (5%)	2 (2%)	0.25
Baseline MD (dB)	-3.52 ± 4.52	-6.05 ± 5.75	< 0.001
Peak IOP (mmHg)	20.5 ± 5.4	23.8 ± 8.6	0.002
Mean IOP (mmHg)	15.3 ± 3.3	15.0 ± 3.1	0.39
CCT (µm)	548.7 ± 34.0	542.5 ± 45.9	0.28
Number of tests	8.1 ± 5.0	8.3 ± 4.4	0.81
Follow-up time (years)	11.0 ± 6.7	10.3 ± 6.1	0.45
Time to blood collection (years)	11.5 ± 6.6	11.4 ± 6.3	0.86
Average MD slope (dB/year)	0.01 ± 0.32	-0.63 ± 0.72	<0.001
Fastest MD slope (dB/year)	-0.10 ± 0.33	-1.06 ± 1.08	<0.001
Average RNFL slope (µm/year)	-0.30 ± 1.42	-0.99 ± 1.59	0.002
Fastest RNFL slope (µm/year)	-0.76 ± 1.37	-1.60 ± 1.86	< 0.001

Table 1. Demographic and clinical characteristics of fast and slow glaucoma progressors.

Values indicate mean \pm standard deviation unless otherwise noted.

CCT: central corneal thickness, IOP: intraocular pressure, MD: mean deviation, RNFL: retinal nerve fiber layer thickness.

Age Acceleration (years)	Mean Difference	95% CI Lower	95% CI Upper	P-value
Horvath	2.93	1.48	4.39	< 0.001
Hannum	1.24	0.03	2.46	0.045
PhenoAge	1.06	-0.51	2.64	0.185
GrimAge	1.49	-0.17	3.14	0.079

Table 2. Differences in epigenetic age acceleration between fast and slow glaucoma progressors.

Note: Age acceleration measures correspond to residuals of the regression between epigenetic age and chronologic age at time of blood collection. Mean difference is calculated as (mean of fast progressors) - (mean of slow progressors). Positive values indicate that fast progressors had higher age acceleration than slow progressors. CI: confidence interval.

Table 3. Results of multivariable logistic regression models for the association between

Variable Horvath		Hannum		PhenoAge		Grim		
	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р
Age Acceleration, y	1.15 (1.07-1.23)	< 0.001	1.07 (1.00-1.15)	0.049	1.04 (0.99-1.10)	0.141	1.07 (1.01-1.14)	0.034
Sex, male	1.56 (0.79-3.07)	0.197	1.47 (0.76-2.87)	0.254	1.29 (0.68-2.45)	0.436	1.59 (0.81-3.15)	0.181
Race, Black/AA	1.03 (0.48-2.23)	0.935	1.11 (0.52-2.34)	0.789	0.92 (0.42-1.98)	0.824	0.82 (0.37-1.79)	0.617
Peak IOP	1.10 (1.04-1.15)	< 0.001	1.09 (1.04-1.15)	0.001	1.09 (1.04-1.15)	0.001	1.09 (1.04-1.14)	0.001
Baseline MD, per dB lower	1.13 (1.05-1.22)	0.001	1.13 (1.05-1.21)	0.001	1.13 (1.05-1.21)	0.001	1.12 (1.05-1.20)	0.001
CCT, per 40µm thinner	1.23 (0.88-1.70)	0.223	1.19 (0.87-1.64)	0.274	1.19 (0.87-1.63)	0.282	1.26 (0.91-1.74)	0.164
Follow-up time, y	1.03 (0.98-1.08)	0.312	1.02 (0.97-1.07)	0.471	1.02 (0.97-1.07)	0.504	1.02 (0.97-1.07)	0.380
Smoking, yes	0.46 (0.08-2.63)	0.380	0.56 (0.10-3.17)	0.512	0.58 (0.10-3.28)	0.537	0.35 (0.06-2.14)	0.255

epigenetic age acceleration and fast glaucoma progression.

AA: African-American, CCT: central corneal thickness, CI: confidence interval, IOP: intraocular pressure, MD: mean deviation, OR: odds ratio. Follow-up time: follow-up time until blood collection







Predicted Probability of Fast Glaucoma Progression